Nuvalent, Inc. (NUVL)
| Market Cap | 8.72B +71.0% |
| Revenue (ttm) | n/a |
| Net Income | -450.07M |
| EPS | -6.05 |
| Shares Out | 79.00M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,169,579 |
| Open | 110.00 |
| Previous Close | 109.27 |
| Day's Range | 108.33 - 112.09 |
| 52-Week Range | 70.25 - 113.02 |
| Beta | 1.15 |
| Analysts | Strong Buy |
| Price Target | 144.52 (+30.92%) |
| Earnings Date | May 7, 2026 |
About NUVL
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 20 analysts, the average rating for NUVL stock is "Strong Buy." The 12-month stock price target is $144.52, which is an increase of 30.92% from the latest price.
News
Nuvalent Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Two U.S. commercial launches are expected this year for ALK and ROS1 programs, with neladalkib showing strong durability and CNS activity in ALK patients. The pipeline includes ongoing pivotal trials and a HER2 program targeting CNS disease, with a new candidate to be announced by year-end.
Nuvalent Slides: Corporate presentation
Nuvalent has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.
Nuvalent announces FDA acceptance of neladalkib NDA, Georg Pirmin Meyer as CIO
Nuvalent (NUVL) announced the acceptance of its new drug application, or NDA, for neladalkib for filing by the FDA. The FDA has granted the application priority review and assigned a…
Nuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC
New Drug Application for neladalkib in TKI pre-treated advanced ALK-positive NSCLC accepted for filing with Priority Review by the FDA with PDUFA target action date of November 27, 2026 Veteran biopha...
Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting
Presentation of pivotal data for neladalkib in TKI pre-treated patients with advanced ALK-positive NSCLC from ALKOVE-1 trial TKI pre-treated data from ALKOVE-1 trial of neladalkib support recent NDA s...
Bernstein starts Nuvalent with an Outperform, calls it ‘best idea and top pick’
Bernstein initiated coverage of Nuvalent (NUVL) with an Outperform rating and $189 price target The firm said “Nuvalent is our best idea and top pick for investors,” adding that it…
Nuvalent initiated with an Outperform at Bernstein
Bernstein initiated coverage of Nuvalent (NUVL) with an Outperform rating and $189 price target
Nuvalent reports Q1 EPS ($1.39), consensus ($1.31)
“The forward momentum continues at Nuvalent (NUVL), with both of our parallel-lead programs advancing toward key US regulatory milestones and the opportunity to bring our first new medicine to patient...
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results
NDA submitted for neladalkib in TKI pre-treated advanced ALK-positive NSCLC NDA for zidesamtinib in TKI pre-treated advanced ROS1-positive NSCLC under FDA review with PDUFA target action date of Septe...
Nuvalent Earnings release: Q1 2026
Nuvalent released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Nuvalent Quarterly report: Q1 2026
Nuvalent has published its Q1 2026 quarterly earnings report on May 7, 2026.
Guardant Health announces multi-year strategic collaboration with Nuvalent
Guardant Health (GH) announced a multi-year strategic collaboration with Nuvalent (NUVL) to support the development and potential commercialization of Nuvalent’s oncology pipeline using the tissue and...
Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced a multi-year strategic collaboration with Nuvalent, Inc. (Nasdaq: NUVL), a...
Nuvalent Proxy statement: Proxy filing
Nuvalent filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Nuvalent Proxy statement: Proxy filing
Nuvalent filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Nuvalent to Present Pivotal Data from ALKOVE-1 Trial of Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC at the 2026 American Society of Clinical Oncology Annual Meeting
Company to also present preliminary data for zidesamtinib in advanced ROS1-positive solid tumors outside of NSCLC from the global ARROS-1 trial CAMBRIDGE, Mass., April 21, 2026 /PRNewswire/ -- Nuvalen...
Nuvalent to present preclinical data for zidesamtinib at AACR meeting
Nuvalent (NUVL) announced new clinical and preclinical data for zidesamtinib, an investigational ROS1-selective inhibitor, to be presented during poster sessions at the American Association for Cancer...
New Clinical and Preclinical Data for Investigational Candidate Zidesamtinib Presented at AACR Annual Meeting 2026
Zidesamtinib demonstrated meaningful clinical activity in subset of TKI pre-treated ROS1-positive NSCLC patients from ARROS-1 trial previously treated with repotrectinib or taletrectinib, including in...
Nuvalent Slides: Corporate presentation
Nuvalent has posted slides in relation to its latest quarterly earnings report, which was published on April 8, 2026.
Nuvalent submits neladalkib NDA to FDA
Nuvalent (NUVL) announced the submission to the FDA of the company’s NDA for neladalkib, an investigational ALK-selective inhibitor, in TKI pre-treated advanced ALK-positive NSCLC. “The advancement of...
Nuvalent Announces Submission of New Drug Application to FDA for Neladalkib in TKI Pre-treated Advanced ALK-positive NSCLC
New Drug Application (NDA) based on data in TKI pre-treated patients from the global ALKOVE-1 Phase 1/2 clinical trial CAMBRIDGE, Mass., April 7, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a ...
Nuvalent initiated with an Overweight at Wells Fargo
Wells Fargo analyst Eva Fortea Verdejo initiated coverage of Nuvalent (NUVL) with an Overweight rating and $116 price target The firm believes the company’s zidesamtinib has “best-in-class” potential ...
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026
CAMBRIDGE, Mass., March 17, 2026 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase...
Nuvalent Transcript: Leerink Global Healthcare Conference 2026
Significant progress was highlighted across ROS1 and ALK programs, with rapid trial enrollment, strong clinical data showing high response rates and durability, and regulatory milestones positioning both drugs for potential approval and commercial launch. Plans include global commercialization and further pipeline expansion.
Nuvalent Transcript: TD Cowen 46th Annual Health Care Conference
Multiple oncology programs are advancing toward key regulatory milestones in 2024, with strong physician and patient advocacy support driving rapid trial enrollment. Lead assets target significant market opportunities in ALK and ROS1 lung cancer, with commercial readiness and global registration strategies in place.